DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Application
Claim(s) 1, 4, 8-10, 22, 26, 27, 30, 40, 47, 54, and 55 are pending and under examination
The following Office Action is in response to Applicant's communication dated 08/27/2026.
RE: Applicant argues Nakamoto does not disclose/anticipate newly added limitations to independent claims 1, 27, and 47.
In response: Newly added limitations by Applicant in present amendment, which are considered and will be addressed in present office action.
RE: Applicant argues Nazor’s 12-60 nucleic acid residues sequence does not cure Nakamoto’s deficiency in sequence length.
In response: Examiner agrees that Nazor’s cited range concerns universal sequence rather than a linker length. The rejection for claims 4 and 30 has been modified to rely on Nakamoto’s 5-100 nt range (consistent with previous Non-final mailed on 06/01/2026) and the obvious principle in In re Aller and In re Peterson, as discuss below.
RE: Applicant argues Lebeck does not cure the deficiencies of Nakamoto or Nazor because Lebeck fails to disclose such a sequence-tagged binding molecule conjugated to a genomic fluor as required by instant claim 1.
In response: The test for obviousness is not whether the features of a secondary reference may be bodily incorporated into the structure of the primary reference; nor is it that the claimed invention must be expressly suggested in any one or all of the references. Rather, the test is what the combined teachings of the references would have suggested to those of ordinary skill in the art. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981).
Modified Claim Rejections - 35 USC § 102
Necessitated by amendment
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Regarding claim 1, Nakamoto discloses method for combining cell enrichment, cell sorting, and/or immunofluorescent cell labeling with genomic analysis using a fluorescently-labeled sequence tagged the method comprising
(a) contacting a cell or a sample of cells with the fluorescently-labeled sequence-tagged specificity determining molecule conjugate; (e.g. contacting binding agents with cells sample; wherein each of cellular component-binding reagents is associated with a specific oligonucleotide comprising a detectable moiety and an identifier sequence [Column 1, lines 40-55])
(b) performing cell enrichment, cell sorting, and/or immunofluorescent cell labeling on the cell or sample of cells; ; (e.g. method includes labeling cells from biological samples and obtaining cells before subjecting cells to downstream analysis to obtain sequence information [column 1, lines 40-column 2 line 19]. The reference also discloses The binding construct enables the binding reagent to be employed for both fluorescence analysis (e.g., cell sorting) [abstract])
(c) performing genomic analysis on the cell or sample of cells after step (b) using the fluorescently-labeled sequence-tagged specificity determining molecule conjugate; (e.g. The binding construct enables the binding reagent to be employed for sequence analysis, such as protein expression profiling) [abstract])
wherein the fluorescent label component is a fluorescently-labeled nucleic acid nanostructure, the specificity determining molecule component is a Sequence-tagged antibody or antigen-binding fragment comprising a PCR primer region, a barcode region and a capture sequence, and is linked to the fluorescent label component by an at least partially double-stranded nucleic acid linker; wherein the specificity determining molecule component is covalently attached to one strand of the at least partially double-stranded nucleic acid linker, the fluorescent label component is covalently attached to the opposite strand of the at least partially double-stranded nucleic acid linker, and the specificity determining molecule component and the fluorescent label component are not covalently attached to each other but instead linked via the hybridization of their respective nucleic acid linker strands. (e.g. claimed features are mapped to Nakamoto’s Fig. 12 and matched with specific sections of the Nakamoto’s patent publication)
PNG
media_image1.png
626
1280
media_image1.png
Greyscale
Regarding claims 8, “independent of the choice of genomic analysis method” limitation is interpreted as requiring the selected cell enrichment, cell sorting, or immunofluorescent cell labeling method do not dictate the selection of genomic analysis method.
Nakamoto further discloses cell separation methods may be selected from any convenient protocol such as flow cytometrically sorting [column 119 lines 15-21], the followed by isolation and generation of barcoded identifier sequences [column 119 lines 22-40]. Nakamoto separately allows any convenient sequencing protocol, including Next Generation Sequence (NGS), and any convenient transcriptome analysis protocol [column 119 lines 41-58]. The disclosures provide separate choices for cell separation and genomic sequencing, without limiting genomic analysis method based on particular selected cell separation method. Additionally, Nakamoto’s Figs 2 and 13 disclose two independent workflows of genomic analysis and immunofluorescent cell labeling respectively.
Regarding claims 9, Nakamoto further discloses cell enrichment and/or cell sorting comprises flow cytometry [column 70, lines 42].
Regarding claim 10, Nakamoto further discloses the genomic analysis comprises next generation sequencing (NGS) [column 74, lines 48-67]
Regarding claim 22, Nakamoto further discloses the degree of labeling (DoL) of the specificity determining molecule component is 1 (e.g. In some embodiments, each cellular component binding reagent can be conjugated with a single oligonucleotide molecule. [column 49 lines 28-30 and column 124 lines 4-6]
Regarding claim 26, Nakamoto further discloses the use of a sequence-tagged fluorescent-label specificity determining molecule conjugate allows data from cell enrichment, cell sorting, and/or immunofluorescent cell labeling to be linked to data from genomic analysis. (e.g. cells are selected based on detectable moieties (flow cytometry) and the same reagent specific oligonucleotide then barcoded, extended, and sequence to determine cellular component target information [column 87, lines 13column 88, line 15])
Regarding claim 27, the claimed composition is disclosed by Nakamoto as set forth in claim 1 rejection, where the claimed features are mapped to the corresponding features shown in Nakamoto’s Fig, 12. Hence, claim 1 rejection apply here.
Regarding claim 40, Nakamoto further discloses at least partially double-stranded nucleic acid linker comprises one or more unique identifying sequence. (e.g. Fig. 12 The binding reagent oligonucleotide 1204 can include a unique identifier sequence 1220 (such as an antibody-specific barcode or a sample indexing sequence). [column 57 lines 36-38])
Regarding claim 47, Nakamoto further discloses kit comprising, the fluorescently-labeled sequence-tagged fluorescent-label specificity determining molecule conjugate of claim 27, or a component thereof; one or more reagents for performing cell enrichment, cell sorting, or immunofluorescent cell labeling, and genomic analysis; one or more of instructions either printed or on an electronic storage medium, buffers, or additional reagents, or packaging materials. (e.g. The kits and compositions can, in some embodiments, comprise a plurality of cellular component binding reagents (e.g., a plurality of protein binding reagents) each conjugated with an oligonucleotide, wherein the oligonucleotide comprises a unique identifier for the cellular component binding reagent, and a plurality of oligonucleotide probes, wherein each of the plurality of oligonucleotide probes comprises a target binding region, a barcode sequence (e.g., a molecular label sequence), wherein the barcode sequence is from a diverse set of unique barcode sequences. In some instances, an oligonucleotide of a cellular component-binding reagent, e.g., as described above, is associated with a detectable moiety, such as a fluorescent moiety. In addition to the above components, the subject kits may further include (in certain embodiments) instructions for practicing the subject methods. [columns 121-124]. Also see claim 27 and claim 1 rejection)
Regarding claim 55, Nakamoto further discloses immunofluorescent cell labeling comprises single- or multi-photon microscopy, intravital microscopy, super resolution microscopy, whole tissue imaging, traditional fluorescence microscopy, immunocytochemistry, or multiplexed, immunohistochemistry [column 113 lines 1-30 and column 115 lines 39-50].
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Nakamoto et al.
Regarding claims 4 and 30, Nakamoto further discloses label nucleic acid that hybridizes to the binding reagent oligonucleotide may vary in length, ranging in some instances from 5 to 100 nt [column 57, lines 16-22], which overlap with the claimed range between 10 and 70 nucleotides. It would have been prima facie obvious to a person of ordinary skill in the art to optimize lengths within the overlapping range to produce linking sequence of 10 and 70 nucleotides from Nakamoto’s range, with reasonable expectation of retaining its disclosed function of connecting fluorescent label to antibody-associated nucleotide through hybridization. See MPEP § 2144.05 "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955); and In re Peterson, 315 F.3d 1325 (Fed. Cir. 2003); "[A] prior art reference that discloses a range encompassing a somewhat narrower claimed range is sufficient to establish a prima facie case of obviousness."
Nakamoto et al. and Bisgin et al.
Regarding claims 54, Nakamoto does not disclose the choice of genomic analysis method is based on the results of the cell enrichment, cell sorting, or immunofluorescent cell labeling.
Bisgin discloses selecting a targeted next generation sequencing assay based on flow cytometry immunophenotyping results. Section 2.4 especially states that “The multigene panels were selected upon the flow cytometric results.” Sections 2.2-2.4 and table 1 associate immunophenotypes with specific set of sequencing panels.
As of the application’s effective filing date, it would have been prima facie obvious to a person of ordinary skill in the art to apply Bisgin’s phenotype guide assay selection to Nakamoto’s workflow to diagnose immune deficiency disorders more efficiently [Bisgin’s abstract]. Additionally, the application of molecular diagnosis by multigene NGS panels broadened the understanding of immune deficiency disorders. Molecular analysis together with conventional immunophenotyping thus is critical in modern disease classification, patient care, and management [Bisgin’s Conclusion section]. This combination represents: (A) Combining prior art elements according to known methods to yield predictable results; and (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art. See KSR International Co. v. Teleflex Inc., 550 U.S. 398, 415-421, USPQ2d 1385, 1395 — 97 (2007) (MPEP § 2143, A and F).
Conclusion
No claims are allowed
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Khai Quynh Tien Pham whose telephone number is (571)272-6998. The examiner can normally be reached M-T, 9-4 ET.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heather Calamita can be reached at (571) 272-2876. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/KHAI QUYNH TIEN PHAM/ Examiner, Art Unit 1684
/JEREMY C FLINDERS/ Primary Examiner, Art Unit 1684